Calidi Biotherapeutics Stock to Reverse Split on Friday, July 31st (NYSEAMERICAN:CLDI)

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI)’s stock is set to reverse split before the market opens on Friday, July 31st. The 1-16 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, July 30th.

Calidi Biotherapeutics Stock Performance

Shares of CLDI stock opened at $0.11 on Thursday. The company has a market capitalization of $2.04 million, a P/E ratio of -0.02 and a beta of 1.30. Calidi Biotherapeutics has a fifty-two week low of $0.10 and a fifty-two week high of $10.92. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.92 and a current ratio of 1.92. The stock has a 50 day moving average price of $0.16 and a two-hundred day moving average price of $0.44.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.43) earnings per share for the quarter.

Institutional Investors Weigh In On Calidi Biotherapeutics

Institutional investors have recently added to or reduced their stakes in the company. DRW Securities LLC bought a new stake in Calidi Biotherapeutics in the 4th quarter worth $173,000. Geode Capital Management LLC increased its position in shares of Calidi Biotherapeutics by 41.7% in the fourth quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after acquiring an additional 12,334 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Calidi Biotherapeutics during the fourth quarter valued at about $25,000. Hedge funds and other institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.